SAFETY OF LONG-TERM OZANIMOD TREATMENT FOR UP TO 4 YEARS BY AGE GROUP IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: AN INTERIM ANALYSIS OF THE TRUE NORTH OPEN-LABEL EXTENSION

被引：0
|
作者：
Siegel, Corey A.
Rubin, David T.
Long, Millie D.
Danese, Silvio
Cross, Raymond K.
Armuzzi, Alessandro
Dignass, Axel
Kobayashi, Taku
Faye, Adam S.
Lama, Sonie
Charles, Lorna
Cetin, Volkan
Petersen, AnnKatrin
Wu, Hsiuanlin
Wang, Dong
Jain, Anjali
Sabino, Joao
机构：
来源：
GASTROENTEROLOGY | 2024年 / 166卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
Su1771
引用
收藏
页码：S805 / S806
页数：2
相关论文
共 50 条
  • [1] Safety of long-term ozanimod treatment for up to 4 years in patients with moderately to severely active Ulcerative Colitis: an interim analysis of the True North open-label extension
    Siegel, C.
    Danese, S.
    Rubin, D. T.
    Sabino, J.
    Long, M. D.
    Cross, R. K.
    Armuzzi, A.
    Blumenstein, I.
    Kobayashi, T.
    Lama, S.
    Charles, L.
    Cetin, V.
    Petersen, A.
    Wu, H.
    Wang, D.
    Jain, A.
    D'Haens, G.
    JOURNAL OF CROHNS & COLITIS, 2024, 18 : I100 - I101
  • [2] Safety of Long-Term Ozanimod Treatment Up to 5 Years in Patients With Moderately to Severely Active Ulcerative Colitis: An Interim Analysis of the True North Open-Label Extension
    Abraham, Bincy P.
    Longman, Randy
    Katsanos, Konstantinos
    Lee, Scott D.
    Kobayashi, Taku
    Bettenworth, Dominik
    Korman, Louis
    Mehra, Dimpy
    Santiago, Norma Ruiz
    Petersen, Annkatrin
    Desai, Manik
    Wu, Hsiuanlin
    Wang, Dong
    Osterman, Mark T.
    Jain, Anjali
    Torres, Joana
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2024, 119 (10S): : S1063 - S1063
  • [3] LONG-TERM SAFETY OF 3 YEARS OF OZANIMOD IN MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: AN INTERIM ANALYSIS OF THE TRUE NORTH OPEN-LABEL EXTENSION
    Abreu, Maria T.
    Danese, Silvio
    Wolf, Douglas C.
    Canavan, James B.
    Jain, Anjali
    Wu, Hsiuanlin
    Petersen, AnnKatrin
    Charles, Lorna
    Afzali, Anita
    Panaccione, Remo
    GASTROENTEROLOGY, 2023, 164 (06) : S208 - S208
  • [4] Long-term safety of 3 years of ozanimod in moderately to severely active ulcerative colitis: an interim analysis of the True North open-label extension
    Panaccione, R.
    Danese, S.
    Wolf, D. C.
    Canavan, J. B.
    Jain, A.
    Wu, H.
    Petersen, A.
    Charles, L.
    Afzali, A.
    Abreu, M. T.
    JOURNAL OF CROHNS & COLITIS, 2023, 17 : 534 - 534
  • [5] Efficacy and Safety of Approximately 3 Years of Continuous Ozanimod in Moderately to Severely Active Ulcerative Colitis: Interim Analysis of the True North Open-label Extension
    Danese, Silvio
    Panaccione, Remo
    Abreu, Maria T.
    Rubin, David T.
    Ghosh, Subrata
    Dignass, Axel
    Afzali, Anita
    Wolf, Douglas C.
    Chiorean, Michael, V
    Vermeire, Severine
    Jain, Anjali
    Charles, Lorna
    Lawlor, Garrett
    Osterman, Mark T.
    Wu, Hsiuanlin
    Canavan, James B.
    Petersen, Annkatrin
    Colombel, Jean-Frederic
    Regueiro, Miguel
    JOURNAL OF CROHNS & COLITIS, 2024, 18 (02): : 264 - 274
  • [6] Long-term safety and efficacy of filgotinib for the treatment of moderately to severely active ulcerative colitis: Interim analysis from up to 4 years of follow-up in the SELECTION open-label long-term extension study
    Feagan, Brian G.
    Matsuoka, Katsuyoshi
    Rogler, Gerhard
    Laharie, David
    Vermeire, Severine
    Danese, Silvio
    Loftus Jr, Edward V.
    Beales, Ian
    Schreiber, Stefan
    Kim, Hyo Jong
    Faes, Margaux
    de Haas, Angela
    Masior, Tomasz
    Rudolph, Christine
    Peyrin-Biroulet, Laurent
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2024, 60 (05) : 563 - 584
  • [7] EXTENDED THERAPY WITH OZANIMOD FOR DELAYED RESPONDERS TO OZANIMOD IN MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: DATA FROM THE TRUE NORTH OPEN-LABEL EXTENSION STUDY
    Panaccione, Remo
    Afzali, Anita
    Hudesman, David
    Lawlor, Garrett
    Osterman, Mark T.
    Eren, Devrim
    Memaj, Arteid
    Regueiro, Miguel D.
    Ghosh, Subrata
    GASTROENTEROLOGY, 2022, 162 (07) : S965 - S965
  • [8] Cardiovascular Safety of Ozanimod in Patients With Ulcerative Colitis: True North and Open-Label Extension Analyses
    Armuzzi, Alessandro
    Cross, Raymond K.
    Lichtenstein, Gary R.
    Hou, Jason
    Deepak, Parakkal
    Regueiro, Miguel
    Wolf, Douglas C.
    Akukwe, Lucy
    Ahmad, Harris A.
    Jain, Anjali
    Kozinn, Marc
    Wu, Hsiuanlin
    Petersen, AnnKatrin
    Charles, Lorna
    Long, Millie
    CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2024, 22 (05) : 1067 - 1076.e3
  • [9] Efficacy and safety of 4 years of continuous ozanimod treatment: an interim analysis of the True North open-label extension study
    D'Haens, G.
    Sands, B. E.
    Ferrante, M.
    Matsuoka, K.
    Lindsay, J. O.
    Blumenstein, I.
    Mehra, D.
    Charles, L.
    Cetin, V.
    Petersen, A.
    Wu, H.
    Wang, D.
    Jain, A.
    Hanauer, S. B.
    JOURNAL OF CROHNS & COLITIS, 2024, 18 : I1814 - I1815
  • [10] RECAPTURE OF RESPONSE WITH OZANIMOD IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS WHO WITHDREW THERAPY: DATA FROM THE TRUE NORTH OPEN-LABEL EXTENSION STUDY
    Afzali, Anita
    Chiorean, Michael V.
    Lawlor, Garrett
    Osterman, Mark T.
    Eren, Devrim
    Memaj, Arteid
    Panaccione, Remo
    Ghosh, Subrata
    GASTROENTEROLOGY, 2022, 162 (07) : S229 - S229
12345